Principle and evolving role of intraperitoneal chemotherapy in ovarian cancer

A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study

(2011) Mark A. Morgan et al.   GYNECOLOGIC ONCOLOGY

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

(2011) Robert A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

(2011) Timothy J. Perren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II Study of Intraperitoneal Carboplatin With Intravenous Paclitaxel in Patients With Suboptimal Residual Epithelial Ovarian or Primary Peritoneal Cancer

(2010) Keiichi Fujiwara et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer

(2010) K. Fujiwara et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

(2010) Ignace Vergote et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dose-dense chemotherapy in advanced ovarian cancer

(2009) Michael A Bookman   LANCET

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

(2009) Noriyuki Katsumata et al.   LANCET